10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
12.64
-0.42 (-3.22%)
At close: Sep 12, 2025, 4:00 PM EDT
12.64
0.00 (0.00%)
After-hours: Sep 12, 2025, 4:16 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
The 12 analysts that cover 10x Genomics stock have a consensus rating of "Buy" and an average price target of $13.54, which forecasts a 7.12% increase in the stock price over the next year. The lowest target is $6.50 and the highest is $18.
Price Target: $13.54 (+7.12%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 8 | 7 | 7 | 7 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 16 | 15 | 15 | 15 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Initiates $15 | Hold | Initiates | $15 | +18.67% | Sep 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +34.49% | Aug 12, 2025 |
| UBS | UBS | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | +2.85% | Aug 8, 2025 |
| Barclays | Barclays | Buy Maintains $13 → $15 | Buy | Maintains | $13 → $15 | +18.67% | Aug 8, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | +2.85% | Jun 26, 2025 |
Financial Forecast
Revenue This Year
621.45M
from 610.79M
Increased by 1.75%
Revenue Next Year
615.54M
from 621.45M
Decreased by -0.95%
EPS This Year
-0.68
from -1.52
EPS Next Year
-0.96
from -0.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 656.6M | 657.7M | |||
| Avg | 621.5M | 615.5M | |||
| Low | 562.2M | 581.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.5% | 5.8% | |||
| Avg | 1.7% | -1.0% | |||
| Low | -7.9% | -6.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.41 | -0.40 | |||
| Avg | -0.68 | -0.96 | |||
| Low | -1.38 | -1.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.